pcn poster

Posters

Establishment of a digital therapeutic alliance in patients living with negative symptoms of schizophrenia

Abstract: Introduction: A patient-digital therapeutic (DTx) bond (digital working alliance [DWA]) may be important for DTx success. We assessed whether patients with experiential negative...

08/20/2024

AXS-05 (Auvelity) in Major Depressive Disorder: Pooled Data From Two Six-Week Controlled Trials (GEMINI and ASCEND)

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion; Auvelity) is a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved for treating ...

08/20/2024

Challenges and Approaches for Managing Psychosis in Advanced Parkinson's Disease: A Case Report

Abstract: Parkinson's Disease (PD) psychosis poses major treatment challenges due to the delicate balance required between managing motor deficits and psychotic symptoms. Treating PD asso...

08/20/2024

A Digital Therapeutic for Treating Major Depressive Disorder: Effectiveness and Safety Results of the MIRAI Randomized Controlled Trial

Abstract: Introduction: Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). This randomized controlled trial evaluated the effectiveness and safety o...

08/20/2024

A Focus on Functional Recovery in MDD: Patient-Centered Strategies to Address Residual Symptoms and Treatment-Emergent Adverse Effects

A variety of multimodal treatments that can address the spectrum of MDD symptom domains and ongoing management challenges, including residual symptoms and treatment-emergent adverse effec...

08/20/2024

Attitudes DriVing regional differences in LAI Antipsychotic utilization for schizophrenia among HCPs, patients, and CaregivErs (ADVANCE) Study: Experiences and Perceptions of LAIs from Caregivers

Abstract: Background: Caregivers play an important role in the lives of people with schizophrenia. This analysis aimed to understand the caregivers’ role and gain their perspective toward...

08/20/2024

Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials

Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...

Bijal Sheth , PharmD;

10/26/2023

Veterans’ Intensive PCMHI Boot Camp (VIP Boot Camp)

Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system

Meghan Rooney , PsyD;

10/26/2023

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial

Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...

Ann Childress , MD;

10/26/2023

Withdrawal Catatonia: A Rare Case of Treatment-Resistant Catatonia Secondary to Quetiapine Withdrawal

Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products